SCHEMBL21189240

SCHEMBL21189240

CCOC(=O)c1cccc2c1OCC[C@@H]2N[S+]([O-])C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MGAM O43451 1/20 0.36
AMY1A P0DUB6 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TDP1 Q9NUW8 2/20 0.34
TRPV1 Q8NER1 3/20 0.33
PDK2 Q15119 1/20 0.33
CDC25A P30304 1/20 0.33
CDC25B P30305 1/20 0.33
CDC25C P30307 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21189239 1.00 TSHR (0.37) TSHRL3MBTL1NPSR1ALDH1A1HSD17B10
SCHEMBL19973539 0.85 TRPV1 (0.36) TRPV1ALOX15
SCHEMBL19973547 0.85 TRPV1 (0.36) TRPV1ALOX15
SCHEMBL19973540 0.85 TRPV1 (0.36) TRPV1ALOX15
SCHEMBL30644700 0.82 DRD2 (0.42) TSHRL3MBTL1ALDH1A1HSD17B10KDM4E
SCHEMBL26705413 0.82 DRD2 (0.42) TSHRL3MBTL1ALDH1A1HSD17B10KDM4E
SCHEMBL21189200 0.82 SMN1; SMN2 (0.37) NPSR1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL21189246 0.82 TSHR (0.43) TSHRL3MBTL1NPSR1ALDH1A1HSD17B10
SCHEMBL21189270 0.80 TAS1R3 (0.41) TSHRL3MBTL1ALDH1A1HSD17B10KDM4E
SCHEMBL21189245 0.80 MEN1 (0.42) TSHRL3MBTL1NPSR1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS TSHR 3232/4885L3MBTL1 2663/4885NPSR1 4645/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS TSHR 3232/4885L3MBTL1 2663/4885NPSR1 4645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.